BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34285295)

  • 1. Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients.
    Woo J; Gwak G; Park I; Bae BN; Lee SK; Chae BJ; Yu J; Lee JE; Kim SW; Nam SJ; Ryu JM
    Sci Rep; 2021 Jul; 11(1):14747. PubMed ID: 34285295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy.
    Apostolova C; Ferroum A; Alhassan B; Prakash I; Basik M; Boileau JF; Martel K; Meterissian S; Villareal Corpuz V; Wong N; Foulkes WD; Wong SM
    Eur J Surg Oncol; 2024 Jun; 50(6):108324. PubMed ID: 38636249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high-risk breast cancer patients.
    Kanana N; Ben David MA; Nissan N; Yagil Y; Shalmon A; Halshtok O; Gotlieb M; Faermann R; Klang E; Samoocha D; Yassin M; Davidson T; Zippel D; Madorsky Feldman D; Friedman E; Kaidar-Person O; Sklair Levy M
    Breast J; 2021 May; 27(5):441-447. PubMed ID: 33576117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1/2 mutation carriers & risk reducing mastectomy: Who undergoes surgery and potential benefits.
    Record SM; Thomas SM; Ntowe K; Chiba A; Plichta JK
    Am J Surg; 2024 Jan; 227():146-152. PubMed ID: 37827871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
    Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
    Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer.
    S Chapman J; Roddy E; Panighetti A; Hwang S; Crawford B; Powell B; Chen LM
    Clin Breast Cancer; 2016 Dec; 16(6):494-499. PubMed ID: 27495996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
    Drooger J; Akdeniz D; Pignol JP; Koppert LB; McCool D; Seynaeve CM; Hooning MJ; Jager A
    Breast Cancer Res Treat; 2015 Nov; 154(1):171-80. PubMed ID: 26467044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice?
    Manoukian S; Alfieri S; Bianchi E; Peissel B; Azzollini J; Borreani C
    Psychooncology; 2019 Sep; 28(9):1871-1878. PubMed ID: 31264307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study.
    Wevers MR; Schmidt MK; Engelhardt EG; Verhoef S; Hooning MJ; Kriege M; Seynaeve C; Collée M; van Asperen CJ; Tollenaar RA; Koppert LB; Witkamp AJ; Rutgers EJ; Aaronson NK; Rookus MA; Ausems MG
    Fam Cancer; 2015 Sep; 14(3):355-63. PubMed ID: 25700605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
    van den Broek AJ; Schmidt MK; van 't Veer LJ; Oldenburg HSA; Rutgers EJ; Russell NS; Smit VTHBM; Voogd AC; Koppert LB; Siesling S; Jobsen JJ; Westenend PJ; van Leeuwen FE; Tollenaar RAEM
    Ann Surg; 2019 Aug; 270(2):364-372. PubMed ID: 29727326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
    Welsh JL; Hoskin TL; Day CN; Thomas AS; Cogswell JA; Couch FJ; Boughey JC
    Ann Surg Oncol; 2017 Oct; 24(10):3067-3072. PubMed ID: 28766224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative Panel Testing for Hereditary Cancer Syndromes Does Not Significantly Impact Time to Surgery for Newly Diagnosed Breast Cancer Patients Compared with BRCA1/2 Testing.
    Murphy AE; Hussain L; Ho C; Dunki-Jacobs E; Lee D; Tameron A; Huelsman K; Rice C; Wexelman BA
    Ann Surg Oncol; 2017 Oct; 24(10):3055-3059. PubMed ID: 28766202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer treatment in mutation carriers: surgical treatment.
    Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
    Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.
    Metcalfe K; Gershman S; Ghadirian P; Lynch HT; Snyder C; Tung N; Kim-Sing C; Eisen A; Foulkes WD; Rosen B; Sun P; Narod SA
    BMJ; 2014 Feb; 348():g226. PubMed ID: 24519767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
    Kwong A; Chu AT
    Asian Pac J Cancer Prev; 2012; 13(5):2241-7. PubMed ID: 22901201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation.
    Stolier AJ; Corsetti RL
    Am Surg; 2005 Dec; 71(12):1031-3. PubMed ID: 16447474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.